Highest-materiality recent filing
Axogen Q2 revenue $69.7M (+23% YoY), raises FY2026 guidance to at least $279M (24% growth)
Revenue $69.7M, up 23.1% YoY; net loss $1.5M ($0.03/sh) vs net income $0.6M ($0.01/sh) in Q2 2025.
Axogen Q1 revenue $61.5M (+27% YoY); raises FY 2026 revenue guidance to at least $270M
Q1 revenue $61.5M, up 26.6% YoY; gross margin expanded to 75.2% from 71.9%.
Axogen Q4 revenue $59.9M (+21%); FY2025 $225.2M; guides 2026 growth >=18%
Q4 revenue $59.9M (+21.3% YoY); net loss $13.2M ($0.28/sh); adjusted net income $3.5M ($0.07/sh).
Axogen prices $124M public offering at $31/share; proceeds to pay off $69.7M credit facility
Pricing of upsized 4M share offering at $31.00/share for gross proceeds of ~$124M (assuming no over-allotment).
Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).
Axogen receives FDA approval of BLA for Avance nerve allograft under Accelerated Approval pathway
FDA approved Biologics License Application for Avance (acellular nerve allograft) for sensory, mixed, motor nerve discontinuities in adults and pediatric patients 1 month+.
Axogen Q3 revenue $60.1M (+23.5% YoY); raises FY revenue guidance to at least $222.8M
Net income of $0.7M ($0.01 EPS) vs net loss of $1.9M in Q3 2024; adjusted EPS $0.12 vs $0.07.
FDA extends PDUFA date for Axogen's Avance Nerve Graft BLA to Dec 5, 2025
FDA deemed Axogen's August 22 submission a Major Amendment, extending PDUFA goal date by three months to Dec 5, 2025.
Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M
Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.
Axogen Q1 revenue $48.6M (+17.4% YoY); appoints Lindsey Hartley as CFO
Q1 revenue $48.6M, up 17.4% YoY; net loss $3.8M ($0.08/share) vs $6.6M loss in Q1 2024.
Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M
Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.
Axogen reports Q4 2024 revenue $49.4M (+15.1% YoY); FY 2024 revenue $187.3M (+17.8%)
Q4 2024 revenue expected $49.4M, up 15.1% YoY; full-year 2024 revenue $187.3M, up 17.8%.
Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA
Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.
Axogen completes BLA submission to FDA for Avance Nerve Graft; priority review requested
FDA submission for Avance Nerve Graft completed under rolling review process on Sept. 6, 2024.
Axogen appoints Michael Dale as CEO; Karen Zaderej steps down, remains advisory
Michael Dale becomes CEO, President, and Director effective August 9, 2024; Karen Zaderej exits CEO role.
Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance
Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.
Axogen Q1 2024 revenue $41.4M (+12.9% YoY); net loss narrows to $6.6M; adj EBITDA turns positive
Revenue $41.4M, up 12.9% YoY; gross margin improved to 78.8% from 77.7%.
Axogen reports Q4 2023 revenue $42.9M (+18.7% YoY); 2024 revenue guidance $177-181M
Q4 net loss $3.9M ($0.09/share) vs $5.4M loss in Q4 2022; adjusted EBITDA turned positive at $0.6M.
Axogen reports preliminary Q4 revenue $42.7M (+18% YoY); CEO Karen Zaderej to retire by Jan 2025
Q4 revenue $42.7M (+18% YoY); FY2023 revenue $158.8M (+15% YoY) at high end of $154-159M guidance.
Axogen appoints Nir Naor as CFO; Peter Mariani departs; FY2023 revenue guidance reaffirmed $154-159M
Nir Naor appointed CFO effective Dec 4, 2023, replacing Peter Mariani who stepped down at Board's request.
Axogen Q3 revenue $41.3M (+12% YoY); maintains FY2023 guidance $154-159M
Revenue $41.3M (+12% YoY); scheduled non-trauma grew ~20%, emergent trauma mid-single digits.
Axogen Q2 revenue $38.2M (+11% YoY); net loss narrows to $6.7M
Revenue $38.2M in Q2 2023, up 11% vs Q2 2022; scheduled procedures grew >20%, trauma low-single-digit.
Axogen Q1 revenue up 18% to $36.7M; net loss narrows; FDA clears Axoguard HA+
Net revenue $36.7M (+18% YoY); net loss $7.1M vs $11.5M prior year.
Axogen reports Q4 revenue $36.2M (+17% YoY); guides FY2023 revenue $154M-$159M
Q4 revenue $36.2M, up 17% YoY; gross margin 83.0%; net loss $5.4M ($0.13/sh).
Axogen's $8M SVB deposits fully protected; moving other assets to JP Morgan
Axogen had $8M cash at SVB, its sole depositor; FDIC guarantees full access as of March 13.
Axogen reports preliminary Q4 2022 revenue of $36.1M, up 16% YoY ex-Avive; FY22 $138.5M, up 12%
Q4 revenue $36.1M, up 14% reported or 16% excluding Avive; FY22 $138.5M, up 9% reported or 12% ex-Avive.
Axogen Q3 revenue $37.0M (+18% YoY); net loss narrows to $4.3M; guidance raised
Net loss $4.3M ($0.10/sh) vs $7.1M loss ($0.17/sh) in Q3 2021; adjusted net loss $0.4M ($0.01/sh).
Axogen Q2 revenue $34.5M (+3% YoY); adjusted net loss narrows to $2.6M; reaffirms FY2022 guidance
Net revenue $34.5M, +3% YoY; ex-Avive (suspended June 2021) revenue grew 9%.
Axogen Q1 rev flat at $31M, net loss widens to $0.20/sh; Avance Phase 3 hits endpoint
Net revenue $31.0M flat YoY; adjusted net loss $8.5M ($0.20/sh) vs $3.1M ($0.08) prior year.
On May 8, 2025, Axogen, Inc. (the “Company”) announced the appointment of Lindsey Hartley as its Chief Financial Officer, effective May 12, 2025
Nir Naor, the Chief Financial Officer (the “CFO”) of the Company, will step down from his role effective May 11, 2025
On August 8, 2024, Axogen, Inc. (the “Company”), announced the appointment of Michael Dale as its Chief Executive Officer (“CEO”) and President, effective August 9, 2024 (the “Effective Date”).
Mr. Gregory Freitag was not re-nominated for re-election.
Angelo Scopelianos notified Axogen, Inc. (the “Company”) of his intention to resign as the Company’s Chief Research and Development Officer no later than March 31, 2024 (the “Separation Date”).
Mr. Mariani’s severance benefits in connection with his departure include a severance amount equal to 12 months of his current base compensation and COBRA benefits for 12 months after he ceased to be an employee of the Company on December 22, 2023 (the “Separation Date”).
Retirement of Karen Zaderej Karen Zaderej, the Chief Executive Officer (the “CEO”) and President of the Company informed the Company of her intention to retire in January 2025.
On December 20, 2023, the board of directors (the “Board”) of Axogen, Inc. (the “Company”) increased the size of the Board from nine directors to ten directors, and appointed Kathy Weiler to fill the newly created vacancy effective December 20, 2023.
Effective upon Mr. Naor’s appointment, Peter Mariani stepped down from his role as the Executive Vice President and Chief Financial Officer of the Company and Axogen Corporation, a Delaware corporation (“AC”) and wholly owned subsidiary of the Company, at the request of the Board.
On December 6, 2023, Axogen, Inc. (the “Company”) announced the appointment of Nir Naor as Chief Financial Officer, effective December 4, 2023.
On September 19, 2023, Mike Donovan, the Vice President of Operations of Axogen, Inc. (the “Company”) informed the Company of his intention to retire, effective March 22, 2024 (the “Retirement Date”).
On October 24, 2022, Mark Gold, M.D. notified Axogen, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board”), including as a member of the Quality, Compliance and Portfolio Management Committee, effective as of 3:00 PM EST on Tuesday, December 13, 2022.
Max materiality 0.85 · Median 0.65 · Most common event earnings